A new tool in the fight against obesity: Orforglipron's substantial weight loss results
Sanatate
European Association for the Study of Diabetes Sep 17 2025 New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity who do not have type 2 diabetes. The study is by Dr Sean Wharton, McMaster University, Hamilton, ON, Canada and Wharton Weight
astăzi